National Heart, Lung, and Blood Institute Support of Cellular Therapies Regenerative Medicine

Chapter
Part of the Stem Cell Biology and Regenerative Medicine book series (STEMCELL)

Abstract

Scientific advances have provided new and unprecedented opportunities for the therapeutic use of stem, progenitor, and differentiated cells for the future treatment of heart, lung, blood, and sleep disorders. Stem and progenitor cells have the potential to replace cells that are damaged or diseased, restore vital functions, and offer the promise of curing disease and ending disabilities. The potential for safe new treatments can only be realized if preclinical and clinical research programs provide the scientific and clinical basis to establish new therapies for regenerative medicine. NHLBI seeks to catalyze translational efforts in this area by supporting key efforts needed for the field’s development. This chapter discusses NHLBI support for cellular therapies and illustrates this support with descriptions of two key programs, one for research centers and the other providing key resources.

Keywords

Toxicity Ischemia Prostaglandin PGE2 PCBC 

References

  1. 1.
    NHLBI Meeting Summaries, Scientific Reports. NHLBI Working Group: Cell-Based Therapies for Regenerative & Reparative Medicine: Vision, Scope, and Directions [homepage on the Internet]. c2002 [updated 2011 Jun 23; cited 2012 May 1]. Executive summary available from http://www.nhlbi.nih.gov/meetings/stemcell_wg.htm; Full report available from http://www.nhlbi.nih.gov/meetings/stemcell_wg.pdf
  2. 2.
    NIH Guide for Grants and Contracts (2004) Specialized Centers for Cell-Based Therapy (SCCT) for Heart, Lung, and Blood Diseases and Data and Coordinating Center (DCC) RFA-HL-04-017 [homepage on the Internet]. c2004 [released 2004 May 19; expired 2004 Sept 22]. Available from http://grants.nih.gov/grants/guide/rfa-files/rfa-hl-04-017.html
  3. 3.
    NHLBI Meeting Summaries, Scientific Reports. NHLBI Working Group: Enhancing Translational Research and Early Phase Trials for Cellular Therapy [homepage on the Internet]. c2008 [updated 2009 Mar; cited 2012 May 1]. Executive summary available from http://www.nhlbi.nih.gov/meetings/workshops/enhance-cell-therapy-exesum.htm
  4. 4.
    NHLBI News & Resources, Press Release. NHLBI Funds New Centers for Cell-Based Therapy: Program Emphasizes Clinical Applications [homepage on the Internet]. c2005 [released 2005 Sep 20; cited 2012 May 1]. Available from http://www.nhlbi.nih.gov/new/press/05-09-29.htm
  5. 5.
    Emmes Corporation. Specialized Centers for Cell-based Therapy (SCCT) Sponsored by the National Heart, Lung and Blood Institute (NHLBI) [homepage on the Internet]. c2009 [updated 2009 Oct 2; cited 2012 May 1]. Available from https://web.emmes.com/study/scct/index.html; Clinical protocols available from https://web.emmes.com/study/scct/protocols/protocols.html; Publication list available from https://web.emmes.com/study/scct/publications/SCCT_Bibliography.pdf
  6. 6.
    Leen AM, Christin A, Myers GD et al (2009) Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114:4283–4292PubMedCrossRefGoogle Scholar
  7. 7.
    Leen AM, Bollard CM, Mendizabal AM et al (2010) Most closely HLA-matched allogeneic virus specific Cytotoxic T-Lymphocytes (CTL) to treat persistent reactivation or infection with adenovirus, CMV and EBV after Hemopoietic Stem Cell Transplantation (HSCT). Paper presented at: American Society of Hematology 52nd annual meeting and exposition, San Diego, 2010, Abs. 829Google Scholar
  8. 8.
    University of Maryland School of Medicine. Progenitor Cell Biology Consortium (PCBC); National Heart, Lung, and Blood Institute [homepage on the Internet]. c2011 [updated 2011 Jul; cited 2012 May 1]. Available from http://www.progenitorcells.org/
  9. 9.
    NIH Guide for Grants and Contracts. Characterizing the Blood Stem Cell Niche (R01); RFA-HL-09-010 [homepage on the Internet]. c2008 [released 2008 Oct 17; expired 2009 Jan 7]. Available from http://grants.nih.gov/grants/guide/rfa-files/rfa-hl-09-010.html
  10. 10.
    NIH Guide for Grants and Contracts. Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01); RFA-HL-11-186 [homepage on the Internet]. c2011 [released 2011 Mar 28; expires 2014 Jan 8]. Available from http://grants1.nih.gov/grants/guide/pa-files/PA-11-186.html
  11. 11.
    Medical College of Wisconsin website. Blood & Marrow Clinical Trials Network; National Heart, Lung, and Blood Institute and National Cancer Institute [homepage on the Internet]. c2009 [updated 2009 Oct 2; cited 2012 May 1]. Available from https://web.emmes.com/study/bmt2/index.html
  12. 12.
    Emmes Corporation. Production Assistance for Cellular Therapies; National Heart, Lung, and Blood Institute [homepage on the Internet]. c2011 [updated 2012 Apr; cited 2012 May 1]. Available from http://www.pactgroup.net/
  13. 13.
    Social & Scientific Systems. Gene Therapy Resource Program; National Heart, Lung, and Blood Institute [homepage on the Internet]. c2011 [cited 2012 May 1]. Available from http://www.gtrp.org/
  14. 14.
    RTI International. Science Moving towArds Research Translation and Therapy (SMARTT); National Heart, Lung, and Blood Institute [homepage on the Internet]. c2011 [updated 2012 Feb 14; cited 2012 May 1]. Available from http://www.nhlbi.nih.gov/new/SMARTT.htm
  15. 15.
    NIH Guide for Grants and Contracts. Early-Phase Clinical Trials for Blood Cell Therapies (R01) RFA-HL-11-204 [homepage on the Internet]. c2011 [released 2011 Apr 20; expires 2013 Jan 8]. Available from http://grants.nih.gov/grants/guide/pa-files/PAR-11-204.htmlGoogle Scholar
  16. 16.
    Stroncek D, Harvath L, Barrett J (2008) National Heart, Lung, and Blood Institute of the National Institutes of Health Forum on immune reconstitution and cellular therapy following hematopoietic stem-cell transplantation. Cytotherapy 4:415–418CrossRefGoogle Scholar
  17. 17.
    Reed W, Noga SJ, Gee AP et al (2009) Production assistance for cellular therapies (PACT): five-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies. Transfusion 49:786–796PubMedCrossRefGoogle Scholar
  18. 18.
    Leen AM, Myers GD, Sili U et al (2006) Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12:1160–1166PubMedCrossRefGoogle Scholar
  19. 19.
    Brunstein CG, Miller JS, Cao Q et al (2010) Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117:1061–1070PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Transfusion Medicine and Cellular Therapeutics Branch, Division of Blood Diseases and ResourcesThe National Heart, Lung, and Blood Institutes, National Institutes of HealthBethesdaUSA
  2. 2.Division of Blood Diseases and ResourcesNational Heart, Lung, and Blood Institutes, National Institutes of HealthBethesdaUSA

Personalised recommendations